New York, May 20, 2026, 12:03 (EDT)
Mesa Laboratories Inc. shares gained 2% to $101.78 late Wednesday morning. About 88,900 shares traded. The small-cap life-science tools company is up ahead of its year-end report next week. Shares moved between $98.52 and $102.52.
Mesa will report its fiscal fourth quarter and full-year results on May 27, for the year that ended March 31. The release is set for around 6 a.m. Eastern time.
Mesa Labs will report its first full-year results with Siddhartha Kadia as president and CEO. Kadia took the top job on April 13. The company said in March that Gary Owens was stepping down after running Mesa since 2017. Chair John Sullivan called Kadia a “proven global executive” in life sciences. Kadia said he was coming in at an “important time.” Mesa Labs
Mesa Labs’ most recent quarter had revenue grow 3.6%, with operating income up 38% to $8.0 million. Adjusted operating income, which strips out some non-cash and unusual items, landed at 26.2% of revenue. Then-CEO Owens called markets in Europe and North America “stable” and said Mesa expected the fourth-quarter momentum to keep up. So far, investors don’t have much new info ahead of the next earnings. Mesa Labs
The stock’s move came as small-caps traded higher. The IWM ETF, which follows the Russell 2000, rose around 2.3%. The QQQ, tracking the Nasdaq 100, was up about 1.4%. SPY, the S&P 500 tracker, added about 0.9%.
Life-science tools names traded mostly mixed. Danaher added roughly 0.5% and Agilent ticked up 0.2%. Thermo Fisher Scientific fell close to 0.9%. Mesa saw a similar pattern with no clear signal from peers.
Mesa is a smaller name and its shares trade less than those others, so the stock sometimes reacts to moves that aren’t clear. The company makes life-science tools and sells quality-control products for use in regulated pharma, healthcare, and medical-device markets.
Mesa set its usual quarterly payout at 16 cents per share, the dividend payable June 15 to shareholders on record as of May 29.
Mesa’s update next week could fall short after Wednesday’s buying. In its recent quarterly filing, Mesa said Clinical Genomics sales stayed pressured by trade issues with China and soft macro trends. The company said China challenges should last into fiscal 2027. Tariffs and a weaker dollar trimmed year-to-date gross margin by around 0.8 points.
Clinical Genomics is still weak. Revenue for the unit dropped 7.1% in the December quarter after sales to Chinese customers fell, even as sales in other regions climbed. Mesa warned that if demand in China keeps slipping, the unit may need to take impairment charges, which would mean writing down goodwill or intangible assets.
Kadia shares got a bump as traders bet the company’s first year-end update will deliver enough gains in biopharma development and sterilization controls to balance out hits from China, tariffs, and currency. The set-up is a straightforward one ahead of the results.
